The Hemolung RAS removes carbon dioxide and delivers oxygen directly
to the blood, allowing a patient’s lungs to rest and heal in cases of
acute respiratory failure. The device received CE Mark approval in
February 2013, and is initially being made available to a select group
of hospitals participating in ALung’s Hemolung Reference Center Program.
“I am very pleased to see this exciting new technology be made
available in France,” said Prof. Alain Combes from La Pitié-Salpétrière
ICU in Paris, who is participating in the Hemolung Reference Center
Program. “In my opinion, there is a lot of promise for extracorporeal
lung support devices like the Hemolung RAS to facilitate better outcomes
in cases of acute respiratory failure.”
ALung has established a direct sales and support organization in
France. “I am very excited to have the opportunity to launch the
Hemolung RAS. We have already received tremendous support from local
physicians who agree that minimally invasive extracorporeal carbon
dioxide removal is an ideal solution for those suffering from
respiratory failure,” said Jean-Michel Dutois, ALung’s Country Manager
for France.
Source: ALung Inc.
